2020
LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy
Chen Y, Jiang T, Zhang H, Gou X, Han C, Wang J, Chen AT, Ma J, Liu J, Chen Z, Jing X, Lei H, Wang Z, Bao Y, Baqri M, Zhu Y, Bindra RS, Hansen JE, Dou J, Huang C, Zhou J. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nature Cell Biology 2020, 22: 1276-1285. PMID: 33005030, PMCID: PMC7962994, DOI: 10.1038/s41556-020-00586-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAtaxia Telangiectasia Mutated ProteinsBrain NeoplasmsBreast NeoplasmsCell ProliferationDNA DamageDNA RepairFemaleGamma RaysHumansMiceMice, Inbred BALB CMice, NudeMutS Homolog 2 ProteinNuclear ProteinsPhosphorylationRadiation-Sensitizing AgentsSignal TransductionTumor Cells, CulturedXenograft Model Antitumor Assays
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily historyA lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors
Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget 2016, 7: 59965-59975. PMID: 27494868, PMCID: PMC5312362, DOI: 10.18632/oncotarget.11015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAntibodies, CatalyticBreast NeoplasmsCell Line, TumorDNADoxorubicinDrug Delivery SystemsFemaleHumansLactic AcidLupus Coagulation InhibitorMammary Neoplasms, AnimalMiceMice, Inbred BALB CNanoparticlesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor MicroenvironmentConceptsDelivery of nanoparticlesDOX-loaded nanoparticlesTumor-targeting mechanismDrug delivery mechanismsAmount of moleculesNanoparticle deliveryLupus anti-DNA autoantibodiesNanoparticlesProof of conceptRelease of DNASurface modificationBind moleculesAutocatalytic effectDelivery mechanismTumor neovasculatureMoleculesDeliveryDoxorubicinTumor microenviromentMajor limitationEfficiencyLigandsSubsequent treatmentToxic agentsDNA
2013
Breast Cancer in Systemic Lupus Erythematosus
Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast Cancer in Systemic Lupus Erythematosus. Oncology 2013, 85: 117-121. PMID: 23887245, PMCID: PMC3934367, DOI: 10.1159/000353138.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusSLE durationHistological typeBreast cancerDuctal carcinomaSLE cohortLupus erythematosusMultivariate logistic regression analysisDuctal histological typeIndependent risk factorCommon histological typeBreast cancer riskLogistic regression analysisRegression analysisLobular adenocarcinomaIndependent predictorsMixed histologyCancer RegistryRisk factorsHistological statusCancer riskCarcinomaHistology informationCancerCancer dates
2009
Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo.
Heinze E, Baldwin S, Chan G, Hansen J, Song J, Clements D, Aragon R, Nishimura R, Reeves M, Weisbart R. Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. International Journal Of Oncology 2009, 35: 167-73. PMID: 19513564, DOI: 10.3892/ijo_00000325.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalApoptosisBreast NeoplasmsCaspase 3Cell Line, TumorCell SurvivalColorectal NeoplasmsDose-Response Relationship, DrugFemaleForkhead Transcription FactorsHumansImmunoconjugatesImmunoglobulin FragmentsLiver NeoplasmsMiceMice, Inbred BALB COvarian NeoplasmsRecombinant Fusion ProteinsTransfectionConceptsColon cancer metastasisCancer cellsCancer metastasisColon cancer cellsBALB/c miceProtein therapyImmune suppressive functionCell deathDose-dependent cell deathRegulatory cellsTumor burdenClinical efficacySyngeneic modelC miceNuclear transcription factorMouse modelSuppressive functionInhibits metastasisMetastasisZ-VAD-FMKClinical potentialTherapyCaspase-3Foxp3Cell killing